FDA's OK could be start of KV's comeback

An inspection thumbs-up from the FDA last week for KV Pharma's Micro-K manufacturing ops marks a milestone in the drugmaker's GMP-violations comeback. The approval gives KV the go-ahead to produce Micro-K, a treatment for low blood potassium.

The approval follows a mid-August inspection that encompassed quality systems, manufacturing processes and facilities, all of which passed FDA muster. "The inspection was successfully completed without the issuance of a FDA 483," the drugmaker trumpets in an announcement. It expects to begin shipping Micro-K this week.

But it's still a partial comeback for KV at this point. More FDA inspections lie ahead for other products. And the outcomes of those inspections will determine whether the agency gives the go-ahead for their manufacturing and marketing.

The company's troubles date from the 2008 recalls of products made at a Missouri generics facility. The recalls were followed by the FDA's seizure of $24 million in products and its shutdown of the plant, as reported.

- here's the KV release
- see more from Reuters

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.